ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1624

Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis.  Alterations Related to Cardiovascular Disease and Endothelial Dysfunction

Nuria Barbarroja1,2, Patricia Ruiz-Limon1, Carlos Perez-Sanchez1, Yolanda Jiménez Gómez1, MariCarmen Abalos-Aguilera1, Pedro Segui3, Pilar Font1, Ángeles Aguirre Zamorano1, Jerusalem Calvo-Gutierrez1, Rafaela Ortega1, M. Carmen Castro Villegas1, Eduardo Collantes-Estévez1, Alejandro Escudero-Contreras1 and Chary Lopez-Pedrera1, 1IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, 2Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, 3IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, Epigenetics, Inflammation, monocytes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Monocytes play a key role in the pathogenesis of the cardiovascular disease (CVD). Three monocyte subsets have been described based on their CD14 and CD16 profile, with different actions in the vascular pathology. The distribution of these monocytes subsets and their epigenetic profile associated with CVD in rheumatoid arthritis (RA) remain unravelled. Objectives: 1) to functionally characterize the monocytes subsets in RA patients and analyze their role in the endothelial dysfunction, altered oxidative status and proinflammatory/prothrombotic profile associated to RA. 2) to evaluate the role of anti-CCPs

Methods:

Thirty RA patients and 15 healthy donors were included. Endothelial function was measured through post occlusive hyperaemia using Laser-Doppler. Carotid intima media thickness (CIMT) was used as atherosclerosis marker. The monocyte subsets were characterized by flow cytometry and isolated by immuno-magnetic selection. Proinflammatory cytokines, peroxides levels and cellular activation markers were analyzed. NanoString nCounter miRNA Expression Array was used to profile 800 microRNAs in isolated CD14+ and CD16+ monocytes. PCR array gene expression was used to analyze the expression of 84 genes related to atherosclerosis. In vitro treatment of T lymphocytes with supernatants of CD14+ or CD16+ precultured cells with or without IgG anti-CCPs was performed.

Results:

CD16+ monocytes were significantly extended in RA patients. These subsets had increased protein and gene expression of proinflammatory cytokines, markers of atherosclerosis and peroxide levels. Isolated CD14+ healthy monocytes treated with IgG anti-CCPs showed increased CD16 and decreased CD14 gene expression after 48 h. Supernatant from CD16+ monocytes treated with IgGs anti-CCPs induced a significant increased expression of inflammatory molecules in T lymphocytes compared to CD14+ or untreated CD16+ supernatants or IgG anti-CCPs directly added to lymphocytes. miRNA expression profiling showed that 38 miRNAs were significantly altered (³2 fold) in CD14+ RA monocytes compared to CD16+ RA monocytes. Functional classification of those miRNAs showed a preponderance of targets mRNAs involved in the pathological process of RA such as inflammatory state, immune response and CVD.                                         .

RA patients had impaired endothelial function, with a reduced perfusion value after ischemia. Increased CD16+ monocytes and reduced CD14+ cells percentage were associated with a pathologic CIMT. Clinical parameters strongly correlated with endothelial dysfunction, decreased percentage of CD14+ monocytes and increased number of CD16+ subsets.

Conclusion:

1) RA patients exhibit an increased number of CD16+ monocytes, which display a specific atherogenic and inflammatory pattern directly associated to the autoimmune profile, the progression of the disease and the altered microvascular function. This atherogenic profile might be associated with an altered epigenetic pattern, and seems to be modulated, at least partially, by anti-CCPs. That data suggest that CD16+ subpopulation might play a key role in the CVD pathogenesis associated with RA.

Funded by CTS7940, PI12/01511, PI2013-0191, SER


Disclosure: N. Barbarroja, None; P. Ruiz-Limon, None; C. Perez-Sanchez, None; Y. Jiménez Gómez, None; M. Abalos-Aguilera, None; P. Segui, None; P. Font, None; Aguirre Zamorano, None; J. Calvo-Gutierrez, None; R. Ortega, None; M. C. Castro Villegas, None; E. Collantes-Estévez, None; A. Escudero-Contreras, None; C. Lopez-Pedrera, None.

To cite this abstract in AMA style:

Barbarroja N, Ruiz-Limon P, Perez-Sanchez C, Jiménez Gómez Y, Abalos-Aguilera M, Segui P, Font P, Aguirre Zamorano , Calvo-Gutierrez J, Ortega R, Castro Villegas MC, Collantes-Estévez E, Escudero-Contreras A, Lopez-Pedrera C. Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis.  Alterations Related to Cardiovascular Disease and Endothelial Dysfunction [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/epigenetic-profiling-of-cd14-and-cd16-monocyte-subtypes-in-rheumatoid-arthritis-alterations-related-to-cardiovascular-disease-and-endothelial-dysfunction/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epigenetic-profiling-of-cd14-and-cd16-monocyte-subtypes-in-rheumatoid-arthritis-alterations-related-to-cardiovascular-disease-and-endothelial-dysfunction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology